Compare Charles River Laboratories Intl. Inc (CRL) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Gap Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $226.11 (market cap $11.14B), while Gap Inc trades at $20.48 (market cap $7.25B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Gap Inc pays a 3.48% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GAP | |
|---|---|---|
Market Cap | $11.14B | $7.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $29.13 |
52-Week Low | $145.57 | $18.35 |
Enterprise Value | $14.00B | $10.33B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Gap Inc. (GAP) trades at $19.80, up 1.75% today, with a bearish technical signal despite neutral oscillators. The stock shows strong fundamentals with a P/E of 7.86 and net income margin of 6.25%, supported by a 10-quarter positive comp trend. Recent news highlights a digital transformation with AI-led marketing and ongoing legal investigations.
The outlook is mixed; valuation metrics suggest upside to the $27 consensus target, but near-term risks include legal probes and Athleta's turnaround pace. Earnings growth and margin expansion remain key catalysts, though investor sentiment is cautious amid bearish technicals and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
